CNS‐directed gene therapy for lysosomal storage diseases
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders usually caused by deficient activity of a single lysosomal enzyme. As most lysosomal enzymes are ubiquitously expressed, a deficiency in a single enzyme can affect multiple organ systems, including the central nervous system (CNS). At least 75% of all LSDs have a significant CNS component. Approaches such as bone marrow transplantation (BMT) or enzyme replacement therapy (ERT) can effectively treat the systemic disease associated with LSDs in some patients. However, CNS disease remains a major challenge. Gene therapy represents a promising approach for the treatment of CNS disease as it has the potential to provide a permanent source of the deficient enzyme. Direct intracranial injection of viral gene transfer vectors has resulted in reduced lysosomal storage and functional improvement in certain small (rodent) and large (canine and feline) animal models of LSDs. The addition of protein transduction domains (PTDs) to the recombinant enzymes increased the distribution of enzyme and the extent of correction. Therapeutic levels of lysosomal enzymes can also be delivered to distant sites in the brain by anterograde and retrograde axonal transport. Finally, combining disparate approaches such as BMT and CNS‐directed gene therapy can increase treatment efficacy in LSDs with severe CNS disease that are refractory to more conventional approaches. Conclusion: The development of gene transfer vectors that mediate persistent expression in vivo, the addition of PTDs, a better understanding of lysosomal enzyme trafficking and combining different therapies provide hope that the CNS component of LSDs can be effectively treated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 1×
“In one case, the AAV vector genome integrated within a 6 kb region of mouse chromosome 12 in the tumours but not in normal-appearing liver tissue (35).”
BackgroundSelf-citationDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“AAV vectors pseudotyped with capsid proteins from AAV serotypes 1, 4 and 5 transduce more cells and have a much greater distribution in the brains of mice compared with the early generation AAV2 vectors (24,25).”
Neufeld, E. F., & Fratantoni, J. C. (1970) · Science · doi:10.1126/science.169.3941.141 · Cited by 215 · cited 1×
“Although lysosomal enzymes are intracellular proteins localized within membrane-bound vesicles, a small proportion of the mature enzymes are secreted from the cell (3).”
BackgroundAAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
Griffey, M., Macauley, S. L., Ogilvie, J. M., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.018 · Cited by 115
Self-citation
Cited by
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Possible strategies to cross the blood–brain barrier
Bellettato, C. M., & Scarpa, M. (2018) · Italian Journal of Pediatrics · doi:10.1186/s13052-018-0563-0 · Cited by 258
AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement
Golebiowski, D., Bradbury, A. M., Kwon, C.-S., van der Bom, I. M. J., Stoica, L., Johnson, A. K., Wilson, D. U., Gray-Edwards, H. L., Hudson, J. A., Johnson, J. A., et al. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_11 · Cited by 6
Metadata
- Authors
- Sands, M. S., & Haskins, M. E.
- Venue
- Acta Paediatrica
- Publisher
- Wiley
- Published
- 2008-03-13
- Volume
- 97
- Issue
- s457
- Pages
- 22-27
- ISSN
- 0365-1436 (ISSN-L)
- 0803-5253
- 1651-2227
- OpenAlex
- W2031826717
- Cited by
- 69
- References
- 6
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CNS‐directed gene therapy for lysosomal storage diseases. https://app.cochat.ai/papers/10.1111/j.1651-2227.2008.00660.x
- The paper
- Sands, M. S., & Haskins, M. E. (2008). CNS‐directed gene therapy for lysosomal storage diseases. Acta Paediatrica. https://doi.org/10.1111/j.1651-2227.2008.00660.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.